{
  "symbol": "UNH",
  "year": 2024,
  "Period": "Q3",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.1722,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.213
  },
  "top_positive": [
    {
      "sent": "FINANCIAL STATEMENTS UnitedHealth Group Condensed Consolidated Balance Sheets (Unaudited) (in millions, except per share data) March 31, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 28,414 $ 25,427 Short-term investments 4,296 4,201 Accounts receivable, net 27,197 21,276 Other current receivables, net 19,284 17,694 Assets under management 3,619 3,755 Prepaid expenses and other current assets 6,132 6,084 Total current assets 88,942 78,437 Long-term investments 45,928 47,609 Property, equipment and capitalized software, net 10,429 11,450 Goodwill 105,664 103,732 Other intangible assets, net 15,543 15,194 Other assets 17,704 17,298 Total assets $ 284,210 $ 273,720 Liabilities, redeemable noncontrolling interests and equity Current liabilities: Medical costs payable $ 34,032 $ 32,395 Accounts payable and accrued liabilities 30,738 31,958 Short-term borrowings and current maturities of long-term debt 9,787 4,274 Unearned revenues 3,206 3,355 Other current liabilities 26,668 27,072 Total current liabilities 104,431 99,054 Long-term debt, less current maturities 63,850 58,263 Deferred income taxes 4,167 3,021 Other liabilities 14,844 14,463 Total liabilities 187,292 174,801 Commitments and contingencies (Note 6) Redeemable noncontrolling interests 4,548 4,498 Equity: Preferred stock, $ 0.001 par value - 10 shares authorized; no shares issued or outstanding \u2014 \u2014 Common stock, $ 0.01 par value - 3,000 shares authorized; 920 and 924 issued and outstanding 9 9 Retained earnings 90,118 95,774 Accumulated other comprehensive loss ( 3,439 ) ( 7,027 ) Nonredeemable noncontrolling interests 5,682 5,665 Total equity 92,370 94,421 Total liabilities, redeemable noncontrolling interests and equity $ 284,210 $ 273,720 See Notes to the Condensed Consolidated Financial Statements 1 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended March 31, (in millions, except per share data) 2024 2023 Revenues: Premiums $ 77,988 $ 72,786 Products 11,909 10,267 Services 8,888 8,080 Investment and other income 1,011 798 Total revenues 99,796 91,931 Operating costs: Medical costs 65,735 59,845 Operating costs 14,077 13,625 Cost of products sold 11,056 9,405 Depreciation and amortization 997 970 Total operating costs 91,865 83,845 Earnings from operations 7,931 8,086 Interest expense ( 844 ) ( 754 ) Loss on sale of subsidiary ( 7,086 ) \u2014 Earnings before income taxes 1 7,332 Provision for income taxes ( 1,222 ) ( 1,558 ) Net (loss) earnings ( 1,221 ) 5,774 Earnings attributable to noncontrolling interests ( 188 ) ( 163 ) Net (loss) earnings attributable to UnitedHealth Group common shareholders $ ( 1,409 ) $ 5,611 (Loss) earnings per share attributable to UnitedHealth Group common shareholders: Basic $ ( 1.53 ) $ 6.01 Diluted $ ( 1.53 ) $ 5.95 Basic weighted-average number of common shares outstanding 922 933 Dilutive effect of common share equivalents \u2014 10 Diluted weighted-average number of common shares outstanding 922 943 Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 15 5 See Notes to the Condensed Consolidated Financial Statements 2 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Comprehensive Income (Unaudited) Three Months Ended March 31, (in millions) 2024 2023 Net (loss) earnings $ ( 1,221 ) $ 5,774 Other comprehensive income: Gross unrealized (losses) gains on investment securities during the period ( 290 ) 640 Income tax effect 68 ( 147 ) Total unrealized (losses) gains, net of tax ( 222 ) 493 Gross reclassification adjustment for net realized (gains) losses included in net earnings ( 32 ) 13 Income tax effect 7 ( 3 ) Total reclassification adjustment, net of tax ( 25 ) 10 Foreign currency translation (losses) gains ( 293 ) 341 Reclassification adjustment for translation losses included in net (loss) earnings 4,128 \u2014 Total foreign currency translation gains 3,835 341 Other comprehensive income 3,588 844 Comprehensive income 2,367 6,618 Comprehensive income attributable to noncontrolling interests ( 188 ) ( 163 ) Comprehensive income attributable to UnitedHealth Group common shareholders $ 2,179 $ 6,455 See Notes to the Condensed Consolidated Financial Statements 3 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Changes in Equity (Unaudited) Common Stock Additional Paid-In Capital Retained Earnings Accumulated Other Comprehensive Loss Nonredeemable Noncontrolling Interests Total Equity Three months ended March 31, (in millions) Shares Amount Net Unrealized (Losses) Gains on Investments Foreign Currency Translation (Losses) Gains Balance at January 1, 2024 924 $ 9 $ \u2014 $ 95,774 $ ( 1,971 ) $ ( 5,056 ) $ 5,665 $ 94,421 Net (loss) earnings ( 1,409 ) 149 ( 1,260 ) Other comprehensive (loss) income ( 247 ) 3,835 3,588 Issuances of common stock, and related tax effects 2 \u2014 242 242 Share-based compensation 352 352 Common share repurchases ( 6 ) \u2014 ( 574 ) ( 2,518 ) ( 3,092 ) Cash dividends paid on common shares ($ 1.88 per share) ( 1,729 ) ( 1,729 ) Redeemable noncontrolling interests fair value and other adjustments ( 20 ) ( 20 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 19 19 Distribution to nonredeemable noncontrolling interests ( 151 ) ( 151 ) Balance at March 31, 2024 920 $ 9 $ \u2014 $ 90,118 $ ( 2,218 ) $ ( 1,221 ) $ 5,682 $ 92,370 Balance at January 1, 2023 934 $ 9 $ \u2014 $ 86,156 $ ( 2,778 ) $ ( 5,615 ) $ 3,678 $ 81,450 Net earnings 5,611 113 5,724 Other comprehensive income 503 341 844 Issuances of common stock, and related tax effects 2 \u2014 350 350 Share-based compensation 366 366 Common share repurchases ( 4 ) \u2014 ( 633 ) ( 1,378 ) ( 2,011 ) Cash dividends paid on common shares ($ 1.65 per share) ( 1,537 ) ( 1,537 ) Redeemable noncontrolling interests fair value and other adjustments ( 83 ) ( 83 ) Acquisition and other adjustments of nonredeemable noncontrolling interests 819 819 Distribution to nonredeemable noncontrolling interests ( 101 ) ( 101 ) Balance at March 31, 2023 932 $ 9 $ \u2014 $ 88,852 $ ( 2,275 ) $ ( 5,274 ) $ 4,509 $ 85,821 See Notes to the Condensed Consolidated Financial Statements 4 Table of Contents UnitedHealth Group Condensed Consolidated Statements of Cash Flows (Unaudited) Three Months Ended March 31, (in millions) 2024 2023 Operating activities Net (loss) earnings $ ( 1,221 ) $ 5,774 Noncash items: Depreciation and amortization 997 970 Deferred income taxes ( 27 ) ( 332 ) Share-based compensation 372 362 Loss on sale of subsidiary 7,086 \u2014 Other, net 179 69 Net change in other operating items, net of effects from acquisitions, dispositions and changes in AARP balances: Accounts receivable ( 6,162 ) ( 4,306 ) Other assets ( 1,927 ) ( 1,875 ) Medical costs payable 2,069 2,467 Accounts payable and other liabilities ( 231 ) 1,796 Unearned revenues 9 11,402 Cash flows from operating activities 1,144 16,327 Investing activities Purchases of investments ( 4,798 ) ( 4,894 ) Sales of investments 2,976 456 Maturities of investments 2,314 2,119 Cash paid for acquisitions, net of cash assumed ( 3,006 ) ( 7,826 ) Purchases of property, equipment and capitalized software ( 743 ) ( 760 ) Other, net ( 3,083 ) ( 115 ) Cash flows used for investing activities ( 6,340 ) ( 11,020 ) Financing activities Common share repurchases ( 3,072 ) ( 2,000 ) Cash dividends paid ( 1,729 ) ( 1,537 ) Proceeds from common stock issuances 486 344 Repayments of long-term debt ( 750 ) ( 1,375 ) Proceeds from short-term borrowings, net 6,189 7,349 Proceeds from issuance of long-term debt 5,925 6,401 Customer funds admin\n ) $ 7,332 13 Table of Contents ITEM\u00a02.",
      "score": 0.9976
    },
    {
      "sent": "The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of March\u00a031, 2024 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): March 31, 2024 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 728 $ 556 $ (3,616) $ (8,439) 1 364 278 (1,860) (4,607) (1) (364) (263) 1,949 5,590 (2) 728 (524) 3,960 12,440 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.",
      "score": 0.9876
    },
    {
      "sent": "The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of March\u00a031, 2024 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages): March 31, 2024 Increase (Decrease) in Market Interest Rate Investment Income\u00a0Per Annum Interest Expense\u00a0Per Annum Fair\u00a0Value\u00a0of Financial Assets Fair\u00a0Value\u00a0of Financial Liabilities 2 % $ 728 $ 556 $ (3,616) $ (8,439) 1 364 278 (1,860) (4,607) (1) (364) (263) 1,949 5,590 (2) 728 (524) 3,960 12,440 Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.",
      "score": 0.9876
    }
  ],
  "top_negative": [
    {
      "sent": "It is possible that future risks and uncertainties resulting from the Change Healthcare cyberattack, including risks related to impacted data, litigation, reputational harm, and regulatory actions could adversely affect our financial condition or results of operations.",
      "score": -0.8934
    },
    {
      "sent": "It is possible that future risks and uncertainties resulting from the Change Healthcare cyberattack, including risks related to impacted data, litigation, reputational harm, and regulatory actions could adversely affect our financial condition or results of operations.",
      "score": -0.8934
    },
    {
      "sent": "It is possible that future risks and uncertainties resulting from the Change Healthcare cyberattack, including risks related to impacted data, litigation, reputational harm, and regulatory actions could adversely affect our financial condition or results of operations.",
      "score": -0.8934
    }
  ],
  "forward_snippets": [
    "Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item\u00a02, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA).",
    "We expect to continue to incur direct response costs and experience business disruption impacts over the remainder of the year, including costs to continue to restore Change Healthcare\u2019s services and the impact of suspended care management activities.",
    "We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being.",
    "We will continue seeking to balance growth and profitability across all these dimensions.",
    "We expect broad-based competition to continue as the industry adapts to individual and employer needs."
  ]
}